Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates

Abstract

For patients with AIDS and expected survival > 3.8 years, low dose TS is better than standard dose TS as the first choice agent for preventing PCP. As patients with AIDS live longer, the routine use of low dose TS will be more than adequate for patients at risk for PCP.